Catalyst Event
Novo Nordisk A/S (NVO) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
3/19/2026, 12:00:00 AM
The U.S. FDA approved Wegovy HD on March 19, 2026, a new higher-dose (7.2 mg) version of its weight-loss drug, which demonstrated a mean weight loss of approximately 21% in trials. The product is scheduled to launch in the U.S. in April 2026.
Korean Translation
2026년 3월 19일 미국 FDA, 체중 감량 효과를 약 21%로 높인 고용량(7.2mg) 버전의 비만 치료제 위고비 HD를 승인함. 2026년 4월 미국 출시 예정임.
Related Recent Events
Novo Nordisk A/S (NVO) · Earnings Release
First quarter 2026 earnings release on May 6, 2026, scheduled.
5/6/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck & Co. is expected to release its Q1 2026 earnings results on or around April 30, 2026, before the market opens. High impact expected as earnings releases often drive price movements exceeding 10%, scheduled.
4/30/2026, 12:00:00 AM
Novartis AG (NVS) · Earnings Release
First quarter 2026 results scheduled for 2026-04-28; high impact expected as a major financial update.
4/28/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Other
The FDA has set a PDUFA target action date of April 28, 2026, for its review of the New Drug Application for doravirine/islatravir, an investigational HIV treatment. Approval typically impacts price by 5-10%, scheduled.
4/28/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Other
Quarterly dividend with an ex-dividend date of April 15, 2026, is scheduled.
4/15/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Other
Quarterly dividend of $1.25 per share, announced on March 11, 2026, with an ex-dividend date of March 27, 2026. This represented a 3.1% increase from the prior dividend.
3/27/2026, 12:00:00 AM